The diagnostic performance of lysine(K)-specific demethylase 6B (KDM6B) in non-small cell lung cancer

Figures & data

Figure 1. Relative expression levels of KDM6B mRNA levels in NSCLC patients and healthy control. Student’s t test indicated that serum level of KDM6B was significantly decreased in NSCLC patients, compared with healthy control. ***: indicated p < .001.

Figure 2. The comparison of KDM6B mRNA levels among NSCLC patients based on their age (A), gender (B), clinical stage (C) and lymph node metastasis (D). *p < .05 and **p < .01 indicated the significant difference between the compared two.

Table 1. Association between KDM6B expression and clinicopathological characteristics of NSCLC patients.

Characteristics	No. of cases N = 115	KDM6B expression		χ^2	p Values
		Low (N = 62)	High (N = 53)
Age (years)
<50	47	24	23	0.260	.610
≥50	68	38	30
Gender
Male	86	44	42	1.308	.308
Female	29	18	11
Smoking index
<400	24	13	11	0.001	.978
≥400	91	49	42
Histological type
Squamous cell carcinoma	73	41	32	0.408	.523
Adenocarinoma	42	21	21
Differentiation
Well and moderate	81	43	38	0.075	.784
Poor	34	19	15
Clinical stage
I–II	77	36	41	4.408	.028
III–IV	38	26	12
Lymph nodes metastasis (N)
N0	68	31	37	4.641	.031
N1 + N2	47	31	16
Tumor size (cm)
<3	74	35	39	3.656	.056
≥3	41	27	14

Figure 3. ROC curve analyses for the diagnostic value of KDM6B in NSCLC. Analysis results suggested that KDM6B could serve as a diagnostic marker for NSCLC with the sensitivity of 79.5% and the specificity of 84.3%. The cut-off value was 0.955 and the AUC was 0.897.

Figure 4. The expression of KDM6B mRNA among healthy controls, NSCLC early stage (stage I–II) and later stage patients (stage III–IV). The results showed the significant difference of KDM6B mRNA level was found between any two groups (p < .05).